Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Patient Preference of Apalutamide vs Enzalutamide in Prostate Cancer
NCT04409288Phase 3Terminated
- Sponsor
- The Chinese University of Hong Kong
- Start
- Jul 2020
- Primary completion
- Oct 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of apalutamide and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by The Chinese University of Hong Kong. Primary endpoint: Patient Preference Questionnaire at 29 weeks. Started Jul 2020; status: terminated.
02
Drugs
apalutamideenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT04409288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04409288.